Your browser doesn't support javascript.
loading
Serum Soluble Tumor Necrosis Factor Receptors 1 and 2 Are Early Prognosis Markers After ST-Segment Elevation Myocardial Infarction.
Paccalet, Alexandre; Crola Da Silva, Claire; Mechtouff, Laura; Amaz, Camille; Varillon, Yvonne; de Bourguignon, Charles; Cartier, Regine; Prieur, Cyril; Tomasevic, Danka; Genot, Nathalie; Leboube, Simon; Derimay, François; Rioufol, Gilles; Bonnefoy-Cudraz, Eric; Mewton, Nathan; Ovize, Michel; Bidaux, Gabriel; Bochaton, Thomas.
Afiliación
  • Paccalet A; INSERM U1060, CarMeN Laboratory, Groupement Hospitalier Est, Université de Lyon, Bron, France.
  • Crola Da Silva C; INSERM U1060, CarMeN Laboratory, Groupement Hospitalier Est, Université de Lyon, Bron, France.
  • Mechtouff L; Stroke Department, Hôpital Wertheimer, Hospices Civils de Lyon, Bron, France.
  • Amaz C; Centre D'investigation Clinique de Lyon, Hôpital Louis Pradel, Hospices Civils de Lyon, Bron, France.
  • Varillon Y; Centre D'investigation Clinique de Lyon, Hôpital Louis Pradel, Hospices Civils de Lyon, Bron, France.
  • de Bourguignon C; Centre D'investigation Clinique de Lyon, Hôpital Louis Pradel, Hospices Civils de Lyon, Bron, France.
  • Cartier R; Centre de Biologie Est, Groupement Hospitalier Est, Hospices Civils de Lyon, Bron, France.
  • Prieur C; Unité de Soins Intensifs Cardiologiques, Hôpital Louis Pradel et Université Claude Bernard, Hospices Civils de Lyon, Bron, France.
  • Tomasevic D; Unité de Soins Intensifs Cardiologiques, Hôpital Louis Pradel et Université Claude Bernard, Hospices Civils de Lyon, Bron, France.
  • Genot N; Unité de Soins Intensifs Cardiologiques, Hôpital Louis Pradel et Université Claude Bernard, Hospices Civils de Lyon, Bron, France.
  • Leboube S; INSERM U1060, CarMeN Laboratory, Groupement Hospitalier Est, Université de Lyon, Bron, France.
  • Derimay F; Department of Interventional Cardiology, Cardiovascular Hospital and Claude-Bernard University, Bron, France.
  • Rioufol G; Department of Interventional Cardiology, Cardiovascular Hospital and Claude-Bernard University, Bron, France.
  • Bonnefoy-Cudraz E; Unité de Soins Intensifs Cardiologiques, Hôpital Louis Pradel et Université Claude Bernard, Hospices Civils de Lyon, Bron, France.
  • Mewton N; INSERM U1060, CarMeN Laboratory, Groupement Hospitalier Est, Université de Lyon, Bron, France.
  • Ovize M; Centre D'investigation Clinique de Lyon, Hôpital Louis Pradel, Hospices Civils de Lyon, Bron, France.
  • Bidaux G; INSERM U1060, CarMeN Laboratory, Groupement Hospitalier Est, Université de Lyon, Bron, France.
  • Bochaton T; Centre D'investigation Clinique de Lyon, Hôpital Louis Pradel, Hospices Civils de Lyon, Bron, France.
Front Pharmacol ; 12: 656928, 2021.
Article en En | MEDLINE | ID: mdl-34539391
Background: As inflammation following ST-segment elevation myocardial infarction (STEMI) is both beneficial and deleterious, there is a need to find new biomarkers of STEMI severity. Objective: We hypothesized that the circulating concentration of the soluble tumor necrosis factor α receptors 1 and 2 (sTNFR1 and sTNFR2) might predict clinical outcomes in STEMI patients. Methods: We enrolled into a prospective cohort 251 consecutive STEMI patients referred to our hospital for percutaneous coronary intervention revascularization. Blood samples were collected at five time points: admission and 4, 24, 48 h, and 1 month after admission to assess sTNFR1 and sTNFR2 serum concentrations. Patients underwent cardiac magnetic resonance imaging at 1 month. Results: sTNFR1 concentration increased at 24 h with a median of 580.5 pg/ml [95% confidence interval (CI): 534.4-645.6]. sTNFR2 increased at 48 h with a median of 2,244.0 pg/ml [95% CI: 2090.0-2,399.0]. Both sTNFR1 and sTNFR2 peak levels were correlated with infarct size and left ventricular end-diastolic volume and inversely correlated with left ventricular ejection fraction. Patients with sTNFR1 or sTNFR2 concentration above the median value were more likely to experience an adverse clinical event within 24 months after STEMI [hazards ratio (HR): 8.8, 95% CI: 4.2-18.6, p < 0.0001 for sTNFR1; HR: 6.1, 95% CI: 2.5 -10.5, p = 0.0003 for sTNFR2]. Soluble TNFR1 was an independent predictor of major adverse cardiovascular events and was more powerful than troponin I (p = 0.04 as compared to the troponin AUC). Conclusion: The circulating sTNFR1 and sTNFR2 are inflammatory markers of morphological and functional injury after STEMI. sTNFR1 appears as an early independent predictor of clinical outcomes in STEMI patients.
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Prognostic_studies Idioma: En Revista: Front Pharmacol Año: 2021 Tipo del documento: Article País de afiliación: Francia Pais de publicación: Suiza
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Prognostic_studies Idioma: En Revista: Front Pharmacol Año: 2021 Tipo del documento: Article País de afiliación: Francia Pais de publicación: Suiza